laquinimod 0.3
LAQ/5062
Phase 2 small_molecule completed
Quick answer
laquinimod 0.3 for Relapsing Remitting Multiple Sclerosis is a Phase 2 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Relapsing Remitting Multiple Sclerosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed